-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism

Benzinga·10/07/2026 15:54:27
Listen to the news

https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu